A newly developed dual-action drug, when combined with chemotherapy, has helped extend the lives of patients with a hard-to-treat lung cancer by an average of 15 per cent, a recent trial has revealed.
The investigational treatment, known as Ivonescimab, effectively disables the "off" switch employed by tumours to evade the immune system, uncloaking cancer cells and allowing the body to recognise and fight the disease. It also targets a specific protein used by tumours to build new blood vessels and grow.
